19 October 2021 - After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second Great Patent Cliff of 2019–2024.
With it we find low-hanging fruit for generic/biosimilar market entrants, and the importance of having an elegant patent strategy enabling early market entry for generics and biosimilars is underscored.